Introduction
Chronic kidney disease (CKD) is a worldwide public health problem. Approximately 16% of the population in Europe and 13% in the United States (US) have CKD [1, 2] . The prevalence and incidence of end-stage renal disease in 2005 among European adults were 808 and 124 per million people (p.m.p), and in the US were 1569 and 347.1 p.m.p, respectively [3, 4] . The 5-year survival rates among dialysis patients are low (Europe: 40.5%, US: 55.2%) and have remained constant over the past decade [3, 4] . Even early CKD patients have poor survival; approximately 25% of these patients die while relatively few reach dialysis [5] . The treatment costs of CKD are high; they have increased 4-fold over the past 10 years to reach 42 billion US dollars, or 12.7% of the total Medicare budget [3] .
CKD is a powerful risk factor and a risk multiplier for poor survival [6] . The mortality rates are considerably higher among CKD patients than among the general population (17.7 versus 5.5/100 patient-years) [7] . A recent analysis identified a 6-to 9-fold higher mortality risk among dialysis patients compared to the non-CKD cohort [8] . Cardiovascular disease (CVD) is the single largest cause of mortality, responsible for 40-50% of deaths among CKD patients [3] . CKD patients are more likely to die of CVD than to develop kidney failure, with mortality rates estimated to be 10-30 times higher in dialysis patients as compared to the healthy population [9] .
The mortality epidemic in CKD patients may be attributed to a high prevalence and longer exposure [10, 11] to traditional CV risk factors (such as diabetes, hypertension, obesity and hypercholesterolaemia) and involvement of new non-traditional risk factors (such as hyperhomocysteinaemia, abnormal lipoprotein levels, chronic inflammation and oxidant stress [12] ). Some CKD patients are at an increased risk of mortality even with low blood pressure and reduced cholesterol, which has been referred to as 'reverse epidemiology' [13] .
Deterioration of kidney function is also accompanied by mineral metabolism disturbances, which include decreased vitamin D and increased phosphorus and parathyroid hormone (PTH) levels. These mineral disturbances begin to develop early with only slight impairment in renal function [14] . However, control of mineral parameters in CKD patients has been poor [15] . Achievement of mineral control has been difficult with traditional treatments such as vitamin D and calcium binders [16] . Newer therapies that target all mineral parameters are expensive, emphasizing the need to understand the relationship between mineral disturbances and survival to make appropriate treatment recommendations.
This study is a systematic review that examines the relationship of mineral disturbances with all-cause mortality and its most common aetiology, CV mortality and CV events in CKD patients. Since there is evidence of discrepancy in results across studies and between observational data and prospective trials, the special focus of this analysis is on addressing methodological and clinical heterogeneity in designs, populations and analytical approaches among studies; this focus differentiates our study from previous reviews [17] .
Methods

Literature review
The MEDLINE, EMBASE and Cochrane databases were systematically searched for English-language articles published from January 1980 to December 2007. The search strategy was comprised of the following medical subject headings (MeSH) and keywords from four categories: population [renal dialysis (MeSH) #1 AND #2 AND #4  2304  6  Second search component  #1 AND #3 AND #4  1986  7  Third search component  #5 OR #6  2916  8 Fourth search component Limit: English (la) AND 1980: 2007 (dp) 2534 The search strategy consisted of four components. The first part of the search combined keywords from 'population', 'mineral parameters' and 'outcomes' categories to capture articles that assessed the relationship between mineral metabolism abnormalities and risk of clinical outcomes in CKD patients. The second component combined keywords from 'population', 'intervention' and 'outcomes' categories to aid in identifying articles that assessed the effect of SHPT interventions in ameliorating the risk of clinical outcomes. The third component was the combination of all articles identified by the first two searches and the exclusion of all duplicate articles. The last component consisted of limiting the search to English-language articles published between January 1980 and December 2007. Table 1 describes the search strategy used to identify the published articles of interest.
For inclusion in the review, the published articles had to meet the following criteria: the subjects were adults (≥18 years of age) with CKD or on dialysis; the clinical outcomes were the risk of all-cause mortality, CV mortality and CV events [myocardial infarction (MI), congestive heart failure (CHF), stroke, transient ischaemic attack (TIA), acute coronary syndrome (ACS)] with mineral disturbances or its treatment with SHPT interventions and the study design was observational or a clinical trial. We focused on both all-cause mortality and CV mortality, as inclusion of only CV mortality as an outcome may be misleading because labelling of CV deaths across the identified studies are usually based upon death certificates that carry a significant risk of misclassification. At the same time, the majority of deaths in the CKD population (40-50%) are attributed to CV causes [3] , which emphasizes the need to focus on both all-cause and CV mortality. Articles were excluded if study designs were case reports, editorials or reviews and if the language of publication was non-English. Articles were also rejected if they assessed indirect surrogate CV outcomes such as vascular calcification and left ventricular hypertrophy (LVH). Vascular calcification and LVH correlate significantly with clinical endpoints and mineral parameters and thus are intermediate and surrogate endpoints for mortality. However, a finding of a significant relationship between mineral disturbances and vascular calcification does not necessarily translate into a significant association between mineral abnormalities and mortality. Thus, assessing clinical fatal endpoints (mortality, CV events) along with their surrogates (vascular calcification, LVH) may contribute to significant methodological heterogeneity.
Using these criteria, two reviewers independently reviewed an identical 10% random sample of the abstracts by guest on November 4, 2016 http://ndt.oxfordjournals.org/ Downloaded from that were identified with the search strategy. Inter-rater agreement was assessed using the kappa statistic, and the remaining abstracts were split evenly between the reviewers once a sufficient level of agreement was achieved (κ > 0.7). The full-text publication was obtained for each accepted abstract, and the review process was repeated for all full-text articles.
Data synthesis
A qualitative analysis was performed to summarize the results of the identified studies. The studies were categorized by type of outcome analysed. The number of studies reporting a significant risk (P < 0.05) of each outcome with abnormalities in every mineral parameter was calculated. The threshold mineral level above which the risk significantly increased was ascertained. Also, the risk of every outcome with mineral levels beyond the K/DOQI-recommended targets (phosphorus: 3.5-5.5 mg/dL; calcium: 8.4-9.5 mg/dL and PTH: 150-300 pg/mL) was measured. Clinical and methodological homogeneity across studies was explored with respect to populations studied [CKD stage, type of dialysis (incident versus prevalent), mode of dialysis (HD versus PD)], exposure assessments (continuous, categorical or dichotomous variable), risk measurements [risk (RR), hazard (HR), or odds ratio (OR)], and the reference mineral levels used in the risk measurement. Table 2 describes the baseline characteristics and level of clinical and methodological heterogeneity across studies. The types of covariates adjusted across the identified studies were also assessed to gain additional information on the consistency of analytical techniques used across studies and the ability to compare results. We captured the type of covariates that were controlled by each identified study in a table (Table 3) and then compared the adjusted covariates across studies to gain insight into the extent of methodological heterogeneity. We measured the number of studies that adjusted for each reported covariate and identified covariates, if any, that were controlled consistently across studies. Furthermore, the effects of treatments on the risk of outcomes were assessed.
The methodology and reporting of the included studies were assessed based on the STROBE statement (The Strengthening the Reporting of Observational Studies in Epidemiology) [18] . The STROBE criteria [18] consist of a checklist of 22 items, which assesses the quality of the following components of an observational study: (1) title and abstract; (2) introduction: background/rationale, objectives; (3) methods: study design, setting, participants, variables, data sources/measurement, bias, study size, quantitative variables, statistical methods; (4) results: participants, descriptive data, outcomes data, main results and (5) discussion: key results, limitation and interpretation. A detailed description of each item along with the assessment of the included studies is reported in Table 4 . In addition, we created a rating score and classified the quality of each publication as good [attained the criteria listed by at least 17 items (75%)], moderate [11-16 items (50%)] or poor (≤10 items).
Results
Literature review
The search strategy identified 2534 references, of which 532 abstracts were selected for full-text review. Thirty-five of these met the inclusion criteria. The majority of rejected full-text articles failed to assess the outcomes of interest. Figure 1 describes the literature review process.
Twenty-seven studies assessed the relationship between mineral metabolism disturbances and CV outcomes and eight evaluated the effect of treating SHPT on outcomes of interest. All-cause mortality (n = 29) was the most commonly assessed outcome, followed by CV mortality (n = 11) and CV events (n = 4). Study designs of 35 studies were observational (n = 32), RCT (n = 1), pooled analysis of RCTs (n = 1) and post hoc analysis of RCT (n = 1). Table 2 outlines the baseline characteristics of identified studies.
All-cause mortality
Twenty-two studies assessed the mortality risk with mineral metabolism disturbances. However, the studies were heterogeneous with respect to type of populations enrolled, used varying methods of mineral parameter assessment and controlled for different covariates. Of 22 studies, seven [22, 24, 30, 32, 34, 38, 39] enrolled incident and the rest, prevalent dialysis/pre-dialysis patients; five studies focused on HD and PD [22, 24, 30, 32, 37] ; 14 studies [19] [20] [21] 23, 25, [27] [28] [29] 33, [35] [36] [37] 40, 41] , HD only and three studies [26, 31, 38] , only pre-dialysis patients. Seven studies [19, 20, 25, 29, 30, 32, 36 ] assessed mineral parameters categorically; six [21, 22, 28, 33, 35, 39] , dichotomously; seven [23, 24, 26, 27, 31, 38, 40] , continuously; one [37] , both categorically and continuously and one [34] used all three techniques. The mineral levels used as a reference in measuring the risk lacked uniformity. The risk was expressed as RR (n = 14) [19, 20, 22, 23, 25, [27] [28] [29] [33] [34] [35] 37, 38, 40] or HR (n = 8) [21, 24, 26, [30] [31] [32] 36, 39] . Furthermore, evidence on the association between K/DOQI targets and mortality risk is limited (n = 4 [20, 21, 32, 39] ).
Only nine [19, 20, 22, 23, 25, 26, 32, 37, 39] of the 22 studies were rated as good quality based upon the STROBE criteria. The quality of the methodology and reporting of data was moderate (n = 8 [21, 24, 27, 30, 31, 34, 36, 38] ) or poor (n = 5 [28, 29, 33, 35, 40] ) in a majority of studies. The major areas of weakness were the lack of assessment of mortality risk with time-dependent changes in mineral markers (n = 19), failure to report the reasons for choosing the adjusted covariates (n = 17), lack of information on the external validity of the results (n = 15) and how the study sample size was determined from the initial patient enrolment (n = 14).
Of a set of 20 covariates considered, only age was adjusted for consistently across studies. Although it is important to control for dialysis vintage due to its positive association with mortality, only nine studies [20, 23, 25, 27, 28, 33, 35, 36, 40] adjusted for it. Very few studies controlled for differences in CKD severity by adjusting glomerular filtration rate (GFR) (n = 2 [31, 38] 22 17 15  3  9  3  2  3 2  9  13 4  2  3 3  7  18  13  3  9 CKD, chronic kidney disease; Ca, calcium; Cr, creatinine; GFR, glomerular filtration rate; Alb, albumin; BMI, body mass index; Hgb, haemoglobin; HCO3, bicarbonate; BP, blood pressure; LDL, low-density lipoprotein; HDL, high density lipoprotein; CV, cardiovascular; P, phosphorus; PTH, parathyroid hormone.
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Items that were of good quality are highlighted and added to achieve a total score out of 22. The description of each item is as follows:
(1) Title/abstract: reporting of study design and a balanced summary of the method and results; (2) Background/rationale: the scientific rationale behind the study has been reported; (3) Objectives: specific objectives and hypotheses have been reported; (4) Study design: key elements of the study design presented early in the paper; (5) Setting: location of the study, relevant dates including periods of enrolment, exposure, follow-up and data collection have been described; (6) Participants: eligibility criteria and source/method of selection of participants described; (7) Variables: outcomes, exposure, predictors, potential confounders and effect modifiers have been clearly defined. The type of confounders and the reasons for its adjustment were reported; (8) Data sources/measurement: for each variable of interest, data source and method of assessment described; (9) Bias: efforts undertaken to address source of bias; (10) Study size: explanation of how the study size was arrived at; (11) quantitative variables: explanation of the handling of the quantitative variables in the analyses; (12) Statistical methods: description of methods used to control confounding, sensitivity analyses and how missing data and lost to follow-up was addressed; (13) Participants: number of individuals reported at each stage of study, e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completed follow-up and analysed; (14) Outcomes not of interest = 210
Total Articles Accepted = 35* Number of studies assessing all-cause mortality=29 Number of studies assessing CV mortality=11
Number of studies assessing CV events=4 *9 articles are common to one or more categories (n = 3 [20, 25, 27] ) or CKD aetiologies (n = 2 [23, 31] [22, 26, 31] ) and cholesterol (n = 3 [20, 22, 31] ). Recently, a U-shaped relationship between bicarbonate and mortality was observed in CKD patients [43] but only two studies controlled for this [20, 25] . Also, the influence of co-medications (vitamin D/phosphate binders) on mortality risk was considered in only three studies [25, 26, 30] . Tables 3 and 5 outline the variations in adjusted covariates and the results of identified studies, respectively.
Phosphorus. Seventeen studies [19, 20, [23] [24] [25] [27] [28] [29] [30] [32] [33] [34] [35] [36] [37] 39, 40] assessed the mortality risk with high phosphorus in dialysis patients; all but one study demonstrated a significant relationship. Of six studies assessing phosphorus continuously [23, 24, 27, 34, 37, 40] , three reported a significant rise in relative risk by 4% [40] , 5% [23] and 26% [34] , respectively, with every 1 mg/dL increase and two, by 56% [37] and 341% [24] , respectively, for every 1 mmol/L increase in phosphorus. The lack of a significant relationship in the remaining study [27] may be attributed to the small number of mortality events and failure to adjust for covariates such as hypertension, smoking and cholesterol. Eight studies used categorical models [19, 20, 25, 29, 30, 32, 34, 36] ; all reported significant increases in mortality risk at higher levels of phosphorus as compared to the reference range. The mortality risk increased significantly at phosphorus levels from 5-5.5 mg/dL (RR: 1. The relationship between high phosphorus and mortality risk remained significant even in pre-dialysis patients [26, 31, 38] . In continuous models, every 1 mg/dL increase in phosphorus was associated with a significant increase in risk by 10% [31] , 33% [26] and 62% [38] in pre-dialysis patients. One study [26] , using a categorical model, reported a significant increase in hazard of all-cause mortality in pre-dialysis patients at phosphorus levels between 3.5-3.9 mg/dL (HR: 1.32), 4-4.4 mg/dL (HR: 1.34), 4.5-4.9 mg/dL (HR: 1.83) and ≥5 mg/dL (HR: 1.9) as compared to the reference level of 2.5-2.9 mg/dL.
Two studies assessed the clinical significance of controlling phosphorus within the K/DOQI targets. A significant mortality risk was observed in HD (HR: 1.4) and PD patients (HR: 1.6) with levels >5.5 mg/dL (reference: 3.5-5.5) [32] . Another study observed a significant amelioration in risk, by 33% in patients with phosphorus within the K/DOQI target [39] .
Three studies [20, 25, 29] in dialysis patients reported a significant risk of mortality with low phosphorus at a cutoff level of <5 mg/dL (reference: 5-6 mg/dL), <3 mg/dL (reference: 5-7 mg/dL) and <4 mg/dL (reference: 4-5).
Calcium. Nine studies [19, 25, 27, 30, 32, 36, 37, 39, 40] assessed the mortality risk with high calcium in dialysis patients; six [25, 27, 30, 36, 39, 40] reported a significant relationship. In studies using continuous models, every 1 mg/dL increase was associated with a significant rise in the relative mortality risk, by 12% [40] and 22% [27] . However, the risk was not significantly higher with a 1 mmol/L increase in calcium [37] . Of five studies analysing calcium categorically [19, 25, 30, 32, 36] , three observed significant increases in the mortality risk with higher calcium levels as compared to the reference range. The mortality risk significantly increased by 11% at calcium levels from 9.7-10.2 mg/dL (reference: ≤8.7) [36] , 52% at >9.73 mg/dL (reference: 8.97-9.33) [30] , 14% at >10.2 mg/dL (reference: ≤8.7) and >10.5 mg/dL (risk estimate: not reported, reference: 9-9.5) [25] . The absence of a significant relationship in the remaining two studies [19, 32] may be attributed to different reference mineral levels and failure to adjust for dialysis vintage and comorbidities.
Two studies assessed the impact of achieving K/DOQI calcium targets (8.4-9.5 mg/dL) on mortality in dialysis patients but reported conflicting results [32, 39] . One study used a dichotomous model and reported that patients with levels within the K/DOQI target had a significantly lower risk (20%) when compared to levels beyond it [39] . On the other hand, categorizing calcium with the K/DOQI target as the reference did not show any significant change in the mortality risk with levels >9.5 mg/dL in either HD or PD patients (HR: 1 and 0.9) [32] . Evidence of the mortality risk with high calcium in pre-dialysis patients is absent. Two [22, 25] of the five studies [19, 22, 25, 30, 32] demonstrated a significant relationship between low calcium and mortality risk. One study identified an increased mortality risk at calcium levels <9 mg/dL upon assessing calcium categorically (reference: 9-9.5) [25] . Another dichotomized calcium and observed a 2.31-fold greater relative risk with levels ≤8.8 mg/dL (reference: >8.8) [22] .
Parathyroid hormone. Eleven studies [19] [20] [21] 25, 27, 30, 32, 36, 37, 39, 40] analysed the relationship between high PTH and risk of all-cause mortality in dialysis patients; only seven [20, 25, 27, 30, 36, 39, 40] showed any significant association. Data on mortality risk with PTH changes in pre-dialysis patients are lacking. Two studies assessed mortality with every 100 pg/mL increase in PTH and reported significant increases in the relative risk, by 1% [40] and 4% [27] , respectively. However, the risk did not increase significantly with a 1 pmol/L increase in PTH levels [37] . Categorical models revealed a significant increase in the mortality risk in only four [20, 25, 30, 36] of the seven studies [19] [20] [21] 25, 30, 32, 36] . The categories of PTH levels at which the mortality risk increased significantly were >300 pg/mL (risk estimate: not reported, reference: 200-300) [25] ; >308 pg/mL (HR, 1.68, reference: 160-308) [30] ; >480 pg/mL (HR: 1.17, reference: ≤37) [36] ; 600-900 pg/mL (RR: 1.08, reference: 150-300) [20] ; 900-1200 pg/mL (RR: 1.18, reference: 150-300) and >1200 pg/mL (RR: 1.24, reference: 150-300).
Four studies [20, 21, 32, 39 ] assessed the association between mortality risk and K/DOQI targets but showed conflicting results depending upon the categorization choices. Categorical analysis identified a significant risk at PTH levels between 600 and 900 pg/mL [20] but not at >300 pg/ mL [21, 32] relative to the reference of 150-300 pg/mL. Analysing PTH dichotomously, one study reported a significant decrease in risk by 11% in patients with levels within the target compared with those beyond it [39] . No significant relationship was observed between low PTH levels and risk of mortality.
Efficacy of SHPT interventions in reducing the risk of mortality.
Seven studies [30, [44] [45] [46] [47] [48] [49] assessed the effect of interventions on mortality risk. Teng et al. [44] observed a significant reduction in risk, by 16% in paricalcitol as compared to calcitriol users (HR: 0.84). The outcome difference may be explained by the non-random assignment of therapies and lack of control of CV co-morbidities, co-medications and risk factors such as hypertension and cholesterol. In contrast, a recent study by Tentori et al. [45] did not identify any significant differences in the mortality rates between doxercalciferol or paricalcitol and calcitriol groups (HR: 0.95). Two studies [30, 46] reported a significant risk reduction among vitamin D as compared to non-users (HR: 0.8 and 0.74) but failed to control for CV risk factors, dialysis vintage and co-medications. A pooled analysis of RCTs [47] reported no significant reduction in mortality among cinacalcet users as compared to standard care (RR = 0.81). This outcome may be explained by the lack of statistical power in the pooled RCTs to identify between-group differences in mortality rates. Two studies [48, 49] compared the efficacy of sevelamer and calcium on mortality risk but showed conflicting results. Suki et al. [48] showed similar rates in sevelamer and calcium groups (15 versus 16.1/100 patient-years). In contrast, Block et al. [49] reported significantly lower rates among sevelamer as compared to the calcium group (5.3 versus 10.6/100 patient-years). However, this finding should be interpreted with caution as switching of medications was allowed and the results were derived from post hoc analysis of an RCT that considered all-cause mortality as a secondary endpoint.
Cardiovascular mortality
Eight studies [23, 27, 31, 40, [50] [51] [52] [53] evaluated the CV mortality risk with mineral disturbances. Of eight studies, six [23, 27, 40, [51] [52] [53] included HD patients only; one [50] , HD and PD patients and one [31] , a CKD stage 3 or 4 population. Only one study [50] evaluated the CV mortality risk with mineral concentrations outside the K/DOQI targets. Only one study [23] was rated to be of 'good' quality as it met the criteria on 18 of the 22 STROBE items. The quality of the remaining studies varied from moderate (n = 4 [27, 31, 50, 52] ) to poor (n = 3 [40, 51, 54] ). Only one study [50] clearly defined the confounders and the reasons for its adjustment. Similarly, only one study [50] assessed the relationship between time-dependent changes in mineral markers and risk of cardiovascular mortality.
Mineral parameters were assessed continuously [27, 31, 40, 51, 53] , dichotomously [50, 52] or both [23] . Of 18 covariates considered, only age was adjusted uniformly. Enormous inconsistency was observed in control of covariates such as dialysis vintage (n = 5) [23, 27, 40, 51, 53] , GFR (n = 1) [31] or creatinine (n = 1) [23, 51] . Traditional CV risk factors were not adjusted uniformly. One study [50] assessed a population of HD and PD patients but did not adjust for the dialysis modality. Methodologies of risk measurement were either RR [23, 27, 40, [51] [52] [53] or HR [31, 50] . Table 6 describes the results of the studies on CV mortality.
Phosphorus. Six studies [23, 27, 40, 50, 52, 54] assessed phosphorus in dialysis patients; all reported a significant risk of CV mortality with high phosphorus. Four studies, assessing phosphorus continuously, reported a significant increase in the relative risk of mortality, by 10% [40] , 9% [53] , 13% [27] or 9% [23] with every increase of 1 mg/dL. Using a dichotomous model, one study [50] assessed the risk with phosphorus levels above the K/DOQI target; a significant risk was noted in HD (HR = 1.5) and PD patients (HR = 2.4) with levels >5.5 mg/dL (reference: 3.5-5.5). Two studies [23, 52] assessed the risk with levels >6.5 mg/dL; the relative risk estimates were significant but differed with reference levels (2.4-6.5 mg/dL: 1.36; <6.5 mg/dL: 2.5). The mortality risk in CKD patients varied depending upon the covariates controlled. In continuous models, a significant association with hyperphosphataemia was observed upon adjustments of demographics and CV risk factors (HR = 1.43). However, the risk was no longer significant after adjustment for the CKD severity [31] .
Calcium. Four studies [27, 40, 50, 53] analysed the CV mortality risk with high calcium in dialysis patients. In continuous models, every 1 mg/dL increase was associated with a significantly higher (13% [40] , 14% [53] and 28% [27] ) relative risk of mortality. However, a dichotomous analysis of the effect of calcium control within K/DOQI targets on CV mortality yielded no significant increase in risk in HD (HR: 1) and PD patients (HR: 1) with levels >9.5 mg/dL (reference: 8.4-9.5) [50] . Only one study assessed the risk in patients with low calcium. The risk with calcium levels <8.4 mg/dL as compared to the reference range of 8.4-9.5 mg/dL was high in PD (HR: 2.8) and HD patients (HR: 1.5) (reference: 8.4-9.5) but did not reach statistical significance [50] .
Parathyroid hormone. Six studies [27, 40, [50] [51] [52] [53] analysed PTH in dialysis patients; five found a significant CV mortality risk with high PTH. As a continuous variable, a 100 pg/mL increase resulted in a significant increase in the relative risk of CV mortality by 2% [40, 53] , 7% [51] and 8% [27] . When analysed dichotomously, a significant increase in risk (RR = 3.9) was found in patients with PTH by guest on November 4, 2016
http://ndt.oxfordjournals.org/ Downloaded from levels >476.1 pg/mL [52] (reference: <476.1). However, it is doubtful whether controlling PTH within the K/DOQI targets decreases the mortality risk, as is evident by a nonsignificant risk in HD (HR = 0.8) and PD patients (HR = 1.3) at levels >300 pg/mL (reference: 150-300) [50] . The relationship of CV mortality with PTH is modest, unlike those of phosphorus and calcium. The CV mortality risk in patients with PTH levels below the lower limit set by K/DOQI or <150 pg/mL (reference: 150-300) was also non-significant in HD (HR = 0.9) and PD patients (HR = 1.2) [50] .
Effect of SHPT interventions in ameliorating risk of cardiovascular mortality.
Three studies [46, 48, 55] assessed the impact of treatments on the CV mortality risk in dialysis patients. Shoji et al. [55] conducted a multivariate analysis and reported a significantly reduced risk among alfacalcidol users as compared to non-users (HR = 0.37). The outcome difference may be explained by unadjusted factors such as co-medications, CV traditional risk factors and severity of CKD. Teng et al. [46] reported a significantly lower incidence of CV mortality with injectable vitamin D as compared to non-users (7.6/100 versus 14.6/100 personyears). However, the study did not control for confounders such as oral vitamin D, phosphate binders, CV medications, CV risk factors and dialysis vintage. An RCT by Suki et al. [48] did not report any significant differences in CV mortality rates between sevelamer or calcium arms (8/100 versus 8.6/100 patient-years; HR = 0.93). However, CV mortality was a secondary endpoint, indicating a lack of statistical power to detect any between-group differences.
Cardiovascular events
Only four studies [22, 26, 36, 56] assessed the risk of CV events with mineral disturbances. Two studies enrolled HD and PD patients [22, 56] ; one, HD [36] and one [26] , predialysis patients. Two [22, 56] enrolled incident dialysis patients, and the rest [36] , chronic. Outcomes assessed included CHF (n = 2) [22, 56] , MI (n = 1) [26] and a composite outcome (MI, CHF, TIA or stroke) (n = 1) [36] . CV events were assessed as primary endpoints in two [36, 56] studies. None of the studies independently assessed stroke, TIA or ACS. Data on the effect of treatments on CV events are lacking. The quality of observational assessing CV events was good in two studies [22, 26] and moderate in the remainder [36, 56] . One study [26] measured mineral parameters as a continuous, two [22, 56] dichotomous and one [36] categorical variable. Among 20 covariates considered, only age, diabetes and hypertension were adjusted for consistently. Nutritional deficiencies, a risk factor for cardiac decompensation, were considered in three [22, 26, 56] of the four studies. CV event traditional risk factors were controlled for inconsistently. Only three studies [26, 36, 56] considered the confounding effect of renal function impairment; they adjusted dialysis vintage or creatinine. Only one study [26] adjusted for the potential treatment effect of CV medications on the risk of CV events. Risk estimates were calculated as HR (n = 2) [26, 36] , RR (n = 1) [22] and OR (n = 1) [56] . Data on the CV event risk with mineral levels beyond the K/DOQI targets were not found. Table 7 reports the results of identified studies.
Phosphorus. Three studies [26, 36, 56] assessed the CV event risk with high phosphorus; all reported a significant relationship. One study [36] assessed 'any CV event' categorically in HD patients; it reported a significant risk at phosphorus levels of 4.5-5.3 mg/dL (HR: 1.06), 5.4-6.3 mg/dL (HR: 1.16), 6.4-7.5 mg/dL (HR: 1.14) and >7.5 mg/dL (HR: 1.25) as compared to the reference range of ≤4.4 mg/dL. Using a dichotomous model identified a significantly higher risk of CHF in HD and PD patients at concentrations ≥6.8 mg/dL (OR = 1.34) as compared to the reference level of <6.8 mg/dL [56] . For every 1 mg/dL increase, the risk of MI in CKD patients significantly increased (HR = 1.35) [26] .
Calcium. Two studies [36, 56] analysed the CV event risk with high calcium in HD patients; both reported a significant relationship. One study assessed calcium categorically and reported a significant risk of any CV event only with severe increases in calcium, >10.2 mg/dL (reference: ≤ 8.7) (HR = 1.08) [36] . However, a dichotomous analysis identified a significantly higher risk of CHF at levels ≥8 mg/dL (reference: <8) (OR = 1.41) [56] . Only one study [22] investigated CHF with low calcium and reported a significantly greater risk of de novo (RR: 2.43) and recurrent CHF (RR: 2.66) with calcium ≤8.8 mg/dL as compared to those with levels >8.8 mg/dL.
Parathyroid hormone. Only one study [36] assessed the risk of 'any CV event' with high PTH in HD patients. This study reported a significant increase in risk with PTH >480 pg/mL (reference: ≤37) (HR = 1.12).
Discussion
This study is a systematic review that compares and contrasts designs, analytical approaches and results of studies on the risk of all-cause mortality, CV mortality and CV events with mineral disturbances among CKD patients. Serious limitations were noted in the number of studies and the methodological quality of evidence. Very few studies (n = 12) focused on the relation between mineral parameters and CV outcomes. Evidence in pre-dialysis patients is scarce (n = 3), which is in contrast to the high prevalence of incipient CKD and its recognition as a risk factor for accelerated CVD. The number of interventional RCTs is highly limited (n = 2).
The observational studies were clinically and methodologically diverse in populations studied and analytical strategies used. Studies assessed prevalent or incident, HD, PD or pre-dialysis patients. Methodologically, the studies were heterogeneous in technique of mineral parameter assessment, method of risk calculation, adjusted covariates and reference mineral levels. Mineral parameters were evaluated categorically, dichotomously or continuously. Categorical analysis is a rigorous technique that captures the threshold range of mineral levels associated with significant risk. In contrast, a continuous model does not identify the threshold level at which the risk begins to increase and tends to force a linear relationship between mineral parameters and outcome risk. Dichotomous analysis prevents the comparability of results across studies. However, fewer than half of the observational studies evaluated mineral parameters categorically (n = 9). A large sample used continuous only (n = 10), dichotomous only (n = 7) or both (n = 1). The mineral levels used as a reference in calculating risk lacked consistency, thus further limiting the ability to compare results across studies. Table 8 describes the variations in method of mineral parameter assessment and risk calculation across studies.
In spite of this heterogeneity, the review identified a significant relationship between mineral parameters and allcause mortality, CV mortality and CV events in dialysis patients. However, data on risk of outcomes in pre-dialysis patients was less conclusive due to limited evidence. Data supports a greater mortality risk with phosphorus followed by calcium and PTH. All but one study assessing phosphorus showed a significant all-cause mortality risk. However, the strong association may be due to 'negative publication bias'. In contrast, the risk of mortality with calcium and PTH was significant in only six of nine studies and seven of eleven studies, respectively. No significant relationship was observed between low PTH levels and risk of all-cause mortality. However, a recent cross-sectional study by Nakai et al. [57] observed a significantly lower risk of all-cause mortality with low PTH levels at a threshold level of 60-119 pg/mL as compared to the reference level of 180-359 pg/mL (HR = 0.891; P = 0.0173). This finding may be attributed to utilization of baseline PTH levels instead of time-dependent PTH levels in the measurement of mortality risk and misclassification of mineral parameter levels due to the cross-sectional nature of the database. The finding needs to be confirmed by assessing the risk of mortality with time-dependent concentration of low PTH levels.
Continuous assessment of mineral parameters in dialysis patients resulted in significant all-cause mortality risk estimates that varied from 1.04-1.26 (every 1 mg/dL increase) and 1.56-3.41 (1 mmol/L increase) for phosphorus, 1.12-1.22 for calcium (1 mg/dL increase) and 1.01-1.04 for PTH (100 pg/mL increase). In dichotomous models, the mortality risk estimates varied from 1.11 (>5.5 versus ≤ 5.5 mg/dL) to 2.11 (>5 versus <5 mg/dL) for high phosphorus. The risk estimates in categorical models ranged from 1.1 (5-5.5 versus 4-5 and 6.4-7.5 versus ≤4.4 mg/dL) to 2.47 (≥11 versus 4-5 mg/dL) for high phosphorus, 1.07 (8.8-9.2 versus ≤8.7 mg/dL) to 1.52 (>9.73 versus 8.97-9.33 mg/dL) for high calcium and 1.08 (600-900 versus 150-300 pg/mL) to 1.68 (>308 versus 160-308 pg/mL) for high PTH.
With respect to CV mortality, continuous assessment of mineral parameters resulted in risk estimates that varied from 1.09-1.13 for phosphorus (every 1 mg/dL increase), 1.13-1.28 for calcium (every 1 mg/dL increase) and 1.02-1.08 for PTH (every 100 pg/mL increase). Dichotomous analysis resulted in risk estimates that varied from 1.36 (>6.5 versus 2.4-6.5 mg/dL) to 2.5 (>6.5 versus <6.5 mg/ dL) for high phosphorus, 1 for high calcium (>9.5 versus 8.4-9.5 mg/dL) and 0.8 (>300 versus 150-300 pg/mL) to 3.9 (>476.1 versus <476.1 pg/mL) for high PTH levels. Described differences in adjusted confounders, reference mineral levels and method of mineral parameter assessment are likely to be the major factors responsible for the variability in observed risk estimates.
This finding is consistent with previous reviews. Kestenbaum et al. [17] reviewed only selected studies and found a significant association of phosphorus, calcium and in some cases PTH with mortality among CKD patients. Our special aim of evaluating the quality and addressing the heterogeneity across all studies differentiates this analysis from the review by Kestenbaum et al. [17] . Nevertheless, the relationship between serum phosphorus and CVD has been further solidified by studies conducted in patients without CKD and/or CVD. A post hoc analysis [58] identified a graded independent relation between high phosphorus and CV risk in prior MI patients; most of them did not have CKD-related overt hyperphosphataemia. A prospective evaluation of Framingham offspring study participants showed a similar relationship in patients without CVD or CKD, thus indicating a direct link between phosphorus and vascular risk [59] . A review by Raggi et al. [60] highlights the contribution of SHPT and vitamin D deficiency-two early CKD complications-to the enormous CVD burden, which may be responsible for the increased mortality risk among CKD patients. Finally, a recent prospective cohort study by Tentori et al. [61] observed a significant risk of mortality with high phosphorus (>7 mg/dL), high calcium (>10 mg/dL) and severe increases in PTH levels (>600 pg/mL).
There are several mechanisms that may explain the association of mineral parameters with greater mortality risk; development of CVD and vascular calcification are the most likely links, followed by infections. High phosphate and calcium may promote calcification by causing osteogenic differentiation of the vascular smooth cells and mineralization of the collagenous extracellular matrix secreted by the differentiated cells [62, 63] . However, there are cases in which elevated concentrations of calcium and phosphate may not induce vascular calcification because of inhibition by pyrophosphate. However, the presence of chronic renal failure may create a deficiency of pyrophosphate activity by increasing levels of tissue non-specific alkaline phosphatase and thus promoting vascular calcification [64, 65] . This calcification is known to be associated with arterial stiffening, increased pulse pressure, decreased coronary perfusion and LVH [66, 67] , all of which might directly contribute to CV mortality [68] . Furthermore, arterial stiffening can create abnormalities in microcirculation and thus cause poor wound healing and infection-related deaths [23] . Excess phosphate may also influence CV risk by increasing PTH or decreasing 1,25-dihydroxyvitamin D levels. PTH excess has been implicated in cardiac fibrosis [69] , impaired cardiac contractility [70] , impaired endothelial vasodilatory function [71] and LVH [72] . Lower levels of vitamin D may decrease cardiac contractility [73] and increase coronary calcification [74] . Lower levels of vitamin D may also lead to upregulation of the renin-angiotensin axis, resulting in the development of hypertension and LVH [75, 76] .
The association between hypophosphataemia and mortality may be due to poor nutritional intake [77] , as well as other non-nutritional factors such as reduced cardiac contractility. These can result in respiratory insufficiency, cardiac arrhythmias and significant bone diseases such as osteomalacia, which may increase the fracture rates [78] . Several studies also demonstrated a significant risk of mortality with low calcium levels. Mechanisms involved include the stimulation of parathyroid glands by low calcium, resulting in excess PTH levels, an important risk factor for CVD and mortality. Also, hypocalcaemia can cause cardiac failure, given the role of calcium in maintaining cardiac contractility [79] .
The significant association of mineral metabolism parameters with CV morbidity may have significant longterm consequences on quality of life. The published literature has shown a significant impact of CV events such as stroke and CHF on various domains of health-related quality of life [80, 81] . Thus, it may be of considerable interest to understand the indirect impact of mineral metabolism disturbances on health-related quality of life. Currently, published data on this topic are lacking and are highly warranted.
Identification of the threshold at which the mortality risk starts to increase significantly is important for clinical practice and development. The threshold level at which the all-cause mortality risk significantly increased varied from 3.5-3.9 mg/dL (reference: 2.5-2.9) to 6.6-7.8 mg/dL (reference: 4.4-5.5) for high phosphorus, <3 mg/dL (reference: 5-7) to <5 mg/dL (reference: 5-6) for low phosphorus, 9.7-10.2 mg/dL (reference: ≤8.7) to >10.5 mg/dL (reference: 9-9.5) for high calcium, ≤8.8 mg/dL (reference: >8.8) to <9 mg/dL (reference: 9-9.5) for low calcium and >300 pg/mL (reference: 200-300) to >480 pg/mL (reference: ≤ 37) for PTH. The threshold level associated with by guest on November 4, 2016 http://ndt.oxfordjournals.org/ Downloaded from significant CV mortality risk varied from >5.5 mg/dL (reference: 3.5-5.5) to >6.5 mg/dL (reference: <6.5) for phosphorus and >476.1 pg/mL (reference: <476.1) for PTH. The threshold level associated with significant CV event risk varied from ≥4.5 mg/dL (reference: ≤4.4) to ≥6.8 mg/ dL (reference: <6.8) for phosphorus, ≥8 mg/dL (reference: <8) to >10.2 mg/dL (reference: ≤8.7) for calcium and >480 pg/mL (reference: ≤37) for PTH. Only some of the threshold levels of phosphorus and calcium are within the recommended K/DOQI targets. Therefore, these guidelines may begin to look lenient and may require reappraisal [82] .
Also, current guidelines for mineral metabolism control were developed based upon observational data, due to paucity of RCT data [82] . Interventional RCTs are long overdue and urgently needed to establish a causal relationship between mineral parameters and risk of patientcentred outcomes. The EVOLVE (Evaluation of Cinacalcet Therapy to Lower CV Events) RCT [83] will try to ascertain the impact of mineral metabolism control on mortality.
Our review has some limitations. The results could not be quantitatively synthesized in a meta-analysis due to the significant clinical and methodological heterogeneity observed across the identified studies. Enormous clinical diversity was observed with respect to enrolled study populations. The enrolled population varied from pre-dialysis, HD or PD patients or a combination of HD and PD. The studies were methodologically heterogeneous in methods of mineral parameter assessment, techniques of risk estimation, mineral levels used as a reference and covariates adjusted. Mineral metabolism parameters were evaluated as categorical, continuous or dichotomous variables. Risk estimates were reported in a diverse manner as a hazard, risk or odds ratio. The reference mineral levels used to measure the risk of clinical outcomes at abnormal mineral levels varied considerably and thus limited the comparability of results across studies. Also, no consistency was observed in the type of covariates adjusted across the identified studies. All of the above factors suggest that across inclusion criteria, populations and methodology across studies, there is a lack of homogeneity needed for pooling results or creating summary estimates across studies via a meta-analysis [84] .
Our review only analysed published articles of interest. Thus, unpublished data as a result of 'negative publication bias' may have been missed by our review. Studies with significant, positive association between mineral metabolism parameters and risk of all-cause mortality, CV mortality or events are more likely to be published as compared to studies with negative, non-significant results resulting in 'negative potential bias' [85, 86] . Thus, a number of studies that did not find any significant relationship between mineral disturbances and clinical outcomes may never get published and thus may have not been included in our review. The presence of publication bias may have resulted in over-representation of positive studies in our systematic review, which in turn may have biased our review towards a positive result. Publication bias is an inherent limitation of any systematic review and should be always taken into account when analysing or reading it.
Conclusions
Serious limitations were observed in the number, quality and methodology of studies that reported the association of mineral metabolism disturbances with risk of all-cause mortality, CV mortality and CV events. In spite of these drawbacks, the data showed a significant risk of assessed outcomes with mineral disturbances. Also, the data supported a greater mortality risk with phosphorus followed by calcium and PTH. Data on clinical risk in pre-dialysis patients were less conclusive due to limited (numerically) evidence. The threshold associated with significant all-cause mortality risk varied from 3.5-3.9 mg/dL to 6.6-7.8 mg/dL for high phosphorus, <3 mg/dL to <5 mg/dL for low phosphorus, 9.7-10.2 mg/dL to >10.5 mg/dL for calcium and >300 pg/mL to >480 pg/mL for PTH. Thresholds at which the CV mortality risk significantly increased were >5.5 and >6.5 mg/dL for phosphorus and >476.1 pg/mL for PTH.
Given these findings it is of the utmost clinical importance to learn whether these associations indicate a cause or are coincidental, to better understand the importance of mineral control in decreasing mortality by conducting additional interventional RCTs and thus to more confidently recommend interventions. Future efforts should focus on systematically reviewing the relationship between mineral metabolism parameters and other important clinical outcomes such as risk of fractures, considering the 4-fold increase in fracture risk identified by the USRDS (United States Renal Data System) in dialysis patients as compared to the general population [3] .
